True Wealth Design
ACTU icon

True Wealth Design’s Actuate Therapeutics ACTU Stock Holding History

True Wealth Design’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-29
Closed -$45 – 2812
2026
Q2 		$45 Buy
29
+15
+107% +$35 ﹤0.01% 2602
2026
Q1 		$39 Buy
14
+13
+1,300% +$54 ﹤0.01% 2583
2025
Q4 		$7 Buy
+1
New +$7 ﹤0.01% 2542

Other funds holding ACTU

BIOS Capital Management
BIOS Capital Management Fort Worth, Texas $34.2M AUM 13.29% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Texas Capital Bank Wealth Management Services
Texas Capital Bank Wealth Management Services Dallas, Texas $1.94B AUM 19.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Rock Creek Group
Rock Creek Group Washington, District of Columbia $1.04B AUM 6.61% 1-Year Est. Return
SFMG Wealth Advisors
SFMG Wealth Advisors Plano, Texas $1.66B AUM 20.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
Empowered Funds
Empowered Funds Havertown, Pennsylvania $21.7B AUM 41.23% 1-Year Est. Return

True Wealth Design's ACTU Position: Q3 2026 in Review

True Wealth Design sold out of Actuate Therapeutics (ACTU) in Q3 2026, closing a stake of 29 shares — an estimated $45 sold.

True Wealth Design first reported a position in ACTU in Q4 2025 and held it in 3 quarters. The position peaked at $45 in Q2 2026. 31 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

  • True Wealth Design reported no remaining Actuate Therapeutics position as of Q3 2026 after selling out during the quarter.
  • True Wealth Design sold 29 Actuate Therapeutics shares in Q3 2026, an estimated $45.
  • True Wealth Design first reported a position in Actuate Therapeutics in Q4 2025 and held it in 3 quarters.
  • True Wealth Design's Actuate Therapeutics position peaked at $45 in Q2 2026.
  • 31 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.